Equity · Healthcare
VYGR
NASDAQVoyager Therapeutics (VYGR)
This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.
- Market cap
- 197.3M USD
- Revenue, year to Dec 2025
- 40.4M USD
- EPS, diluted, year to Dec 2025
- −2.04 USD
- 52-week range
- 3 USD – 5.33 USD
- Avg volume
- 164.6K
as of Jul 17, 2026
Have Voyager Therapeutics (VYGR) insiders bought or sold shares recently?
In the 90 days to 22 Nov 2026, no Voyager Therapeutics insider bought or sold shares on the open market; all 2 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4).
Form 4, 90 days to 22 Nov 2026, newest Form 4 filing 1 Nov 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 01 Nov 2026 | Carter Todd AlfredChief Scientific Officer | Award | 33,000 | |
| 01 Nov 2026 | Swartz RobinPresident | Award | 68,250 |
Which funds hold Voyager Therapeutics (VYGR)?
8 of the 45 institutional funds we track reported a Voyager Therapeutics position for the quarter ended 30 Sep 2026 — a combined 19.1M USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Millennium Management | Held (±25%) | 4,878,208 | 13.1M USD | +9.8% |
| Two Sigma Investments | Held (±25%) | 843,666 | 2.3M USD | −11.1% |
| Renaissance Technologies | Held (±25%) | 406,604 | 1.1M USD | −17.9% |
| Citadel Advisors | Trimmed | 323,918 | 868K USD | −58.7% |
| Point72 Asset Management | Held (±25%) | 278,800 | 747K USD | +18.1% |
| Marshall Wace | Added | 215,856 | 578K USD | +54.8% |
| AQR Capital Management | Trimmed | 163,187 | 437K USD | −54.2% |
| D. E. Shaw & Co. | Trimmed | 18,963 | 51K USD | −86.8% |
What has been filed or recorded for Voyager Therapeutics (VYGR)?
The filings we hold for Voyager Therapeutics, newest first: 2 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 14 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 14 Oct 2026 | Fails to deliver | Shares failed to deliver | 175 shares | 376 USD notional · <0.001% of shares out |
| 13 Oct 2026 | Fails to deliver | Shares failed to deliver | 175 shares | 397 USD notional · <0.001% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.40 USD | |
| 30 Sep 2026 | Financials | Total assets | 177.1M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 135.1M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.40 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.47 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −2.04 USD | |
| 31 Dec 2025 | Financials | Revenue | 40.4M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −119.7M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −2.04 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.47 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.57 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.53 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −1.13 USD |
What do people ask about Voyager Therapeutics (VYGR)?
What is Voyager Therapeutics’ market cap?197.3M
Voyager Therapeutics is worth 197.3M USD by market value as of 17 Jul 2026, which is the share price times the shares on issue from its SEC filings.
What is Voyager Therapeutics’ revenue?40.4M
Voyager Therapeutics reported revenue of 40.4M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Voyager Therapeutics insiders bought or sold shares recently?2 filings
In the 90 days to 22 Nov 2026, no Voyager Therapeutics insider bought or sold shares on the open market; all 2 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4). See Insiders
Which funds own Voyager Therapeutics?8 of 45
8 of the 45 funds we track reported a Voyager Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Millennium Management, Two Sigma Investments and Renaissance Technologies. See Funds
When did Voyager Therapeutics last report earnings?−0.40
Voyager Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.40 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close)
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings
- SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words